Holen Sie sich die Stockscreener-App
14.80
0.67%
-0.10
Handel nachbörslich:
14.77
-0.03
-0.20%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt RDY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$14.90
Offen:
$14.77
24-Stunden-Volumen:
2.54M
Relative Volume:
2.02
Marktkapitalisierung:
$2.47B
Einnahmen:
$3.47B
Nettoeinkommen (Verlust:
$668.83M
KGV:
3.6883
EPS:
4.0127
Netto-Cashflow:
$253.46M
1W Leistung:
-3.01%
1M Leistung:
-3.71%
6M Leistung:
-5.27%
1J Leistung:
+9.00%
1-Tages-Spanne:
$14.72
$14.87
1-Wochen-Bereich:
$14.72
$15.33
52-Wochen-Spanne:
$13.47
$16.89
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Vergleichen Sie RDY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RDY
Dr Reddys Laboratories Ltd Adr
|
14.80 | 2.47B | 3.47B | 668.83M | 253.46M | 4.0127 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Herabstufung | Nomura | Buy → Neutral |
| 2024-01-11 | Herabstufung | Jefferies | Buy → Underperform |
| 2023-08-29 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-05-18 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-30 | Eingeleitet | JP Morgan | Underweight |
| 2022-11-14 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Fortgesetzt | BofA Securities | Neutral |
| 2021-07-27 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-09-18 | Hochstufung | Investec | Sell → Hold |
| 2020-01-28 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-27 | Herabstufung | CLSA | Buy → Outperform |
| 2020-01-09 | Hochstufung | Citigroup | Sell → Buy |
| 2019-11-04 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Hochstufung | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Hochstufung | Macquarie | Neutral → Outperform |
| 2019-06-20 | Eingeleitet | Deutsche Bank | Hold |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Hochstufung | CLSA | Outperform → Buy |
| 2019-01-17 | Herabstufung | Citigroup | Neutral → Sell |
| 2017-09-21 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Hochstufung | CLSA | Underperform → Outperform |
| 2017-07-28 | Herabstufung | CLSA | Underperform → Sell |
| 2016-07-27 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Herabstufung | Jefferies | Hold → Underperform |
| 2016-02-10 | Hochstufung | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Herabstufung | Citigroup | Buy → Neutral |
Alle ansehen
Dr Reddys Laboratories Ltd Adr Aktie (RDY) Neueste Nachrichten
Junshi Biosciences Announces Toripalimab’s Approval in Australia - GlobeNewswire Inc.
Asian Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading - MSN
Asian Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading - MSN
Dr Reddy’s Labs Q3 Results FY 2025 date and time: Quarterly earnings announcement schedule - ET Now
Weekly Upgrades and Downgrades - InvestorPlace
Asian Equities Traded in the US as ADRs Rise in Thursday Trading - MSN
Stock Market News Today Live Updates on December 20, 2024 : Top Gainers and Losers today on 20 December, 2024: Dr Reddys Laboratories, ICICI Bank, Tech Mahindra, Trent among most active stocks; Check full list here | Stock Market News - Mint
Dr Reddy’s shares jump over 4 per cent on upgrade by NomuraMarket News - The Financial Express
Zopiclone Market Forecast: Trends and Investment - openPR
Dr Reddy's Laboratories Share Price Live Updates: Disclosure Under Regulation 30 Of SEBI (LODR) Regulatio... - The Economic Times
Dr Reddy’s will top up base business with innovation in India: M V Ramana - BusinessLine
ADR, GDR Listings of Indian companies - Goodreturns
Asian Equities Traded in the US as American Depositary Receipts Edge Down in Wednesday Trading - MSN
NVO Stock Quote Price and Forecast - CNN
Dr Reddy's Labs tanks over 3% after USFDA inspects Hyderabad API facility - Business Standard
Stocks to watch on November 21: Adani Group stocks, Dr Reddy's, Godrej Properties, Tata Power, GRSE, UPL, Bharti Airtel - Upstox
Asian Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading - MSN
Dr Reddy's shares fall 3% as pharma major receives 7 observations from USFDA; check details - Upstox
Asian Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading - MSN
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading - MSN
Jharkhand Elections Phase 2: Richest candidate declares assets worth Rs 402 cr – Check list of top 10 wealthiest candidates - The Financial Express
Jharkhand Phase 2 Elections 2024: 122 candidates with serious criminal cases get tickets, shows ADR report - The Financial Express
Dr. Reddy's Laboratories Limited Just Missed EPS By 12%: Here's What Analysts Think Will Happen Next - Simply Wall St
Earnings call: Dr. Reddy's reports robust growth and strategic expansions By Investing.com - Investing.com Australia
Earnings call: Dr. Reddy's reports robust growth and strategic expansions - Investing.com India
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA - Investing.com India
Dr. Reddy's stock poised for recovery with new US launches and global OTC gains—BofA By Investing.com - Investing.com South Africa
Dr. Reddy’s Labs ADR earnings missed by $0.85, revenue topped estimates - Investing.com Australia
Q2 results today: Titan, Dr Reddy's among 63 companies to announce earnings on Tuesday - The Economic Times
Dr Reddy’s Q2FY25 earnings preview: Expectations of steady revenue growth but margins under pressure - MSN
Dr Reddys Q2FY25 earnings preview: Expectations of steady revenue growth but margins under pressure - Zee Business
Asian Equities Traded in the US as American Depositary Receipts Climb Higher Friday - MSN
BP Faces Price Forecast Cuts As Analysts Flag Weak Earnings And Rising Debt Challenges - Yahoo Finance
Dr. Reddys Share Price Today Down 3% - Equitymaster
Dr Reddy's Labs shares down 80% today? DRL stock turns ex-split - Business Today
Maharashtra: 93% MLAs crorepatis, 60% with criminal cases against them – know the composition of outgoing assembly | Mint - Mint
Saudi Arabia Heparin Market Size & Outlook, 2023-2030 - Grand View Research
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading - MSN
Indian stock market: 8 things that changed for market overnight- Gift Nifty, US retail sales, ECB rate cut to Q2 results | Stock Market News - Mint
Infosys, Wipro ADRs down 3% on NYSE after Q2 results even as S&P, Dow drift near record-highs | Stock Market News - Mint
Nestle India Q2 Results: Margin Misses Estimates As It Slips To 2022 Levels - NDTV Profit
Top gainers and losers for today on October 16: HDFC Life, Dr Reddy’s Labs, Grasim lead NIFTY movers - Upstox
1:5 Stock Split By Large-Cap Pharma Stock; Record DateOct 28: Buy Dr Reddy's For Rs 7,300 Target - Goodreturns
Denmark Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Saudi Arabia Basal Cell Carcinoma Treatment Market Size & Outlook, 2030 - Grand View Research
Finanzdaten der Dr Reddys Laboratories Ltd Adr-Aktie (RDY)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.14%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):